Scipher and Savant Bio Partner to Build Comprehensive Rheumatoid Arthritis Dataset

Scipher Medicine, a leader in precision immunology, and Savant Bio, a Roivant-backed health data infrastructure company, have announced an expanded strategic partnership aimed at building the world's most advanced clinicogenomic dataset in rheumatoid arthritis (RA). This collaboration focuses on generating high-resolution insights to advance academic research, refine clinical trial designs, and improve therapeutic strategies, ultimately enhancing real-world evidence generation. The partnership centers on transforming real-world data from the electronic health records (EHRs) of patients tested with Scipher’s clinically validated molecular signature test, PrismRA®. PrismRA® is specifically designed to predict non-response to TNF inhibitor therapies, which are commonly used to manage RA. This data, when structured and integrated with deep genomic insights, will provide actionable real-world evidence to accelerate drug development in RA and related autoimmune conditions. Brian Moriarty, Co-Founder of Savant Bio, emphasized the untapped potential of real-world clinical data, which often resides in unstructured formats such as physician notes and pathology reports. By leveraging Savant’s platform, which utilizes large language models (LLMs) and domain-specific quality controls, this raw data will be converted into structured, analysis-ready formats. The key enriched dimensions include biologic sequencing, disease activity scores (e.g., CDAI, DAS28), steroid exposure, radiographic findings, and treatment durability. Each output will undergo rigorous review to ensure accuracy and consistency, and can be linked to claims, labs, and prescribing data for comprehensive longitudinal analysis. Reg Seeto, CEO of Scipher Medicine, highlighted his company’s role as a leader in autoimmune transcriptomic data. He stated that combining molecular precision with real-world outcomes is crucial for advancing drug development in autoimmune diseases. By integrating structured clinical data through Savant’s platform, Scipher aims to enhance the utility of its growing dataset for various applications, including clinical trial design and market access. This integration supports the development of more personalized and evidence-driven treatment strategies for RA and other autoimmune diseases. The initial phase of the project involves structuring data from a cohort of more than 6,000 patients who have been tested with PrismRA®. This effort is expected to create one of the most comprehensive genomically defined RA datasets with structured EHR data. Future plans include further expanding the dataset to cover additional patients and conditions. The enriched dataset will be available through collaborative research initiatives, co-publications, and structured licensing partnerships, inviting interested organizations to participate early to shape use cases and gain preliminary access to valuable insights. This partnership leverages the strengths of both companies. Scipher Medicine’s Precision Immunology platform and the largest genomic biobank in RA, combined with over 3 million EHR-connected rheumatology patients, provide a robust foundation. Savant Bio’s expertise in converting unstructured data into structured formats using LLMs and rigorous quality controls ensures that the data is reliable and useful for detailed analysis. One of the primary goals of this dataset is to facilitate faster and more efficient studies. Traditional methods of data collection and analysis can be time-consuming and prone to errors, particularly when dealing with unstructured data. By addressing these issues, the collaboration aims to reduce the time and cost associated with clinical trials and drug development, ultimately bringing more effective treatments to patients sooner. Additionally, the dataset will support richer evidence-based therapies. The integration of genomic and clinical data will allow researchers to identify biomarkers and treatment patterns that predict better patient outcomes, leading to more targeted and personalized treatment approaches. This could significantly improve the management and treatment of RA, reducing the number of patients who do not respond to TNF inhibitors, a common issue in current care. The partnership also aims to enhance market access for new drugs. Real-world evidence is increasingly valued by regulatory bodies and payers, and a comprehensive clinicogenomic dataset can provide the robust evidence needed to support the approval and reimbursement of new therapies. This dataset can also inform therapeutic strategies by identifying subpopulations that may benefit most from specific treatments. Industry insiders have praised this collaboration for its potential to revolutionize RA research and treatment. Peter Schueler, a renowned rheumatologist, noted, "The combination of advanced genomics and structured real-world data is a game-changer for understanding and treating rheumatoid arthritis. It will enable more precise and effective therapies, benefiting both patients and healthcare providers." Scipher Medicine, founded with a mission to redefine drug development in autoimmune diseases, has established itself as a leader in this field through its cutting-edge Precision Immunology platform and extensive genomic biobank. The company's approach to using molecular signatures to guide therapeutic selection has already shown promising results in improving treatment outcomes. Savant Bio, backed by Roivant, is at the forefront of healthcare data abstraction. Using advanced LLMs and rigorous quality controls, Savant’s platform can efficiently and accurately convert complex, unstructured clinical data into structured formats. This capability makes it a valuable ally in generating actionable insights that can drive innovation in medical research and healthcare delivery. Together, Scipher Medicine and Savant Bio are paving the way for a new era of precision medicine in rheumatoid arthritis and related autoimmune conditions. Their collaboration not only accelerates drug development but also enhances the understanding of treatment responses, potentially improving patient care and outcomes on a broad scale.